← Human Trials & Peer-Reviewed Studies
Effects of Sustained Inflation or Positive Pressure Ventilation on the Release of Adrenomedullin in Preterm Infants with Respiratory Failure at Birth
Plain-language guide to PMID 31238370 (2019): randomized controlled trial study of Adrenomedullin in 44 infants.
Key Facts
- PMID
- 31238370
- Journal
- American journal of perinatology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- La Verde A et al. (7 authors)
- DOI
- 10.1055/s-0039-1692133
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Adrenomedullin.
Therefore, in a cohort of low birth weight infants (LBW), the researchers investigated the effects of two different lung recruitment maneuvers, such as positive pressure ventilation (PPV) and sustained inflation (SI) on adrenomedullin (AM), a well-established lung-specific vasoactive agent.
Who Took Part
The study group was 44 infants.
PubMed tags the participants as both men and women.
AM assessment in urine samples was performed at 1-hour (URT1) and at 24-hour (URT2).
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Adrenomedullin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
This is a prospective case-control randomized study in 44 LBW infants spontaneously breathing with respiratory failure at birth requiring respiratory support.
LBW were randomized to receive PPV (n = 22) or SI (n = 22) support.
AM was measured from blood in samples collected at birth from arterial artery (BLT0) and at 1-hour (BLT1) and at 24-hour (BLT2) from peripheral venous site.
What Was Measured
The subject headings attached to it are Adrenomedullin, Biomarkers, Case-Control Studies, Continuous Positive Airway Pressure, Infant, Low Birth Weight, Infant, Premature and Positive-Pressure Respiration.
What This Means in Plain Language
The paper is a randomized study of Adrenomedullin in 44 infants.
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (American journal of perinatology), a journal based in United States.
More context: the Adrenomedullin compound page, all human trials.
Our Notes on the Compound
Adrenomedullin: A 52-amino-acid peptide that widens blood vessels; studied as an infusion in heart, lung and gut conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.